Glenmark Pharmaceuticals Ltd's Q4FY25 Quarter Results
- 24 May 2025
Result Summary
- Glenmark Pharmaceuticals Ltd reported a 12.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 15.1%.
- Its expenses for the quarter were down by 3.5% QoQ and 5.5% YoY.
- The net profit decreased 448.9% QoQ and increased 201.2% YoY.
- The earnings per share (EPS) of Glenmark Pharmaceuticals Ltd declined at 43.2 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 3836.12 | 3418.68 | 3333.50 | 12.2% | 15.1% |
Total Expenses | 2858.51 | 2962.35 | 3024.54 | -3.5% | -5.5% |
Profit Before Tax | 530.83 | 456.33 | -490.77 | 16.3% | -208.2% |
Tax | 1769.47 | 108.30 | -87.63 | 1533.9% | -2119.3% |
Profit After Tax | -1214.27 | 348.03 | -403.13 | -448.9% | 201.2% |
Earnings Per Share | -43.20 | 12.30 | -15.20 | -451.2% | 184.2% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Glenmark Pharmaceuticals Ltd is a leading pharmaceutical company that operates in the healthcare industry, specializing in the development and marketing of branded and generic formulations. The company is known for its focus on therapeutic areas such as dermatology, respiratory, and oncology, along with a significant presence in the generic drug market. Headquartered in India, Glenmark has a global presence with operations spanning across multiple countries. Recent developments in the company have included expanding its product pipeline and strategic partnerships to enhance its market reach and product offerings. However, specific recent events or initiatives were not mentioned in the provided data.
Revenue
In Q4FY25, Glenmark Pharmaceuticals Ltd reported a total income of ₹3836.12 crores, reflecting a robust growth of 12.2% quarter-over-quarter (QoQ) compared to ₹3418.68 crores in Q3FY25. On a year-over-year (YoY) basis, the company's total income increased by 15.1% from the ₹3333.50 crores reported in Q4FY24. This increase in revenue suggests strong operational performance and market demand for the company's products during this period. The consistent rise in total income over the periods under review indicates Glenmark's capability to generate higher sales and expand its market footprint.
Profitability
Glenmark Pharmaceuticals Ltd's profitability metrics show a mixed performance in Q4FY25. The company recorded a profit before tax of ₹530.83 crores, marking an increase of 16.3% QoQ from ₹456.33 crores in Q3FY25. However, despite this improvement, the profit after tax was a negative ₹1214.27 crores in Q4FY25, a significant decline from a positive ₹348.03 crores in Q3FY25. Year-over-year, the profit after tax showed an improvement from a loss of ₹403.13 crores in Q4FY24. The tax expenditure for Q4FY25 was ₹1769.47 crores, significantly higher than previous quarters, which impacted the profit after tax. The earnings per share also reflected this downturn, with a negative value of ₹43.20 in Q4FY25 compared to ₹12.30 in Q3FY25 and negative ₹15.20 in Q4FY24.
Operating Metrics
The operational aspect of Glenmark Pharmaceuticals Ltd during Q4FY25 highlights a reduction in total expenses to ₹2858.51 crores, a decrease of 3.5% from ₹2962.35 crores in Q3FY25. This reduction was also observed on a YoY basis, with expenses decreasing by 5.5% from ₹3024.54 crores in Q4FY24. Despite the decrease in expenses, the company's profitability was adversely affected by the substantial tax outlay in Q4FY25. The earnings per share also followed a similar trend, declining significantly QoQ and YoY. The company's ability to control and reduce expenses while managing other financial obligations would be a key area to watch in the subsequent periods.